INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, ...

An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...

Discover upcoming breakthroughs in Type 1 Diabetes & B-cell disorder treatments, market growth to $24B by 2031, and key ...

AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on discovery ...

Two new RCTs of rituximab will soon begin in the United Kingdom: A biomarker-based trial with add-on belimumab and another in ...

Margrit Wiesendanger, MD, PhD, explores lupus symptoms, diagnosis challenges, and the importance of early detection to prevent inflammation-related damage.

a drug that depletes B cells, since its approval in 2017. It's commonly used to manage conditions like multiple sclerosis, lupus and certain cancers but it may also weaken long-term vaccine ...

Total Operating Expenses: Total operating expenses were $42.9 million for the first quarter of 2025, including research and ...

Oklahoma scientists find interferon-beta may help MS patients on B cell therapy fight infections like flu and Covid-19, new ...

a drug that depletes B cells, since its approval in 2017. It's commonly used to manage conditions like multiple sclerosis, lupus and certain cancers but it may also weaken long-term vaccine ...